Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective tissue, synovial fluid, and the extracellular matrix. Exogenous preparations are used for viscosupplementation, ophthalmology, and dermatological applications. Viscosupplementation products (e.g., Synvisc, Euflexxa) are cross-linked or non-cross-linked polymers derived from avian combs or bacterial fermentation.
## Primary Indications
* **Osteoarthritis:** Management of knee pain in patients who have failed conservative non-pharmacologic therapy and simple analgesics.
* **Ophthalmology:** Surgical aid in cataract extraction, intraocular lens implantation, and corneal transplant.
* **Dermatology/Aesthetics:** Facial tissue augmentation and skin hydration.
## Adult Dosing
* **Knee Osteoarthritis (Intra-articular):**
* **Hylan G-F 20 (Synvisc):** 2 mL (16 mg) injected into the synovial space once weekly for 3 weeks; maximum 6 months per course.
* **Sodium Hyaluronate (Euflexxa):** 2 mL (20 mg) injected once weekly for 3 weeks.
* **Note:** Dosing varies significantly by specific product viscosity and molecular weight; refer to specific manufacturer labeling.
* **Ocular Surgery:** Varies by product; injected into the anterior chamber as required to maintain space.
## Pediatric Dosing
Safety and efficacy have not been established for osteoarthritis in pediatric patients. Use in pediatric ophthalmic or dermatological procedures should be determined by institutional protocol and specialist judgment.
## Dose Adjustments
* **Geriatric:** No specific adjustments required, though caution is advised in patients with chronic joint inflammation or severe baseline joint deformities.
* **Renal/Hepatic:** Not systemically absorbed when used intra-articularly or topically; no adjustments required.
## Contraindications
* Hypersensitivity to hyaluronate or avian-derived proteins (for avian-sourced products).
* Active joint infections or severe inflammation in the target joint.
* Skin infections at or near the injection site.
## Adverse Effects
* **Injection Site:** Arthralgia, effusion, stiffness, swelling, and localized pain (often transient).
* **Systemic:** Rare cases of anaphylactoid reactions or hypersensitivity.
* **Ophthalmic:** Transient increased intraocular pressure, inflammation (iritis, uveitis).
## Key Drug Interactions
* **Quaternary Ammonium Salts:** Do not use with benzalkonium chloride (used in some sterile skin prep solutions), as it may cause precipitation of hyaluronic acid.
* **Disinfectants:** Avoid quaternary ammonium-containing agents at the injection site.
## Monitoring
* **Local:** Assess for signs of hemarthrosis or acute septic arthritis (severe redness, warmth, fever) post-injection.
* **Ocular:** Monitor intraocular pressure post-operatively in ophthalmic use.
## Clinical Pearls
* **Efficacy:** Generally considered a second- or third-line treatment for knee osteoarthritis. Clinical benefit may not be immediate and often peaks 4–8 weeks post-injection.
* **Product Selection:** Patients with known allergies to bird proteins (eggs, feathers) should use bio-fermented (non-avian) products.
* **Technique:** Proper aseptic technique is mandatory to prevent septic arthritis. Avoid strenuous activities for 48 hours post-injection.
***
**Educational Disclaimer:** This information is for educational purposes only. Hyaluronic acid products vary widely in molecular weight and indication. Always verify the current prescribing information, package inserts, and hospital-specific guidelines before ordering or administering medication.
